CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

CELL BIOCHEMISTRY AND FUNCTION is a prominent journal dedicated to disseminating high-quality research in the fields of biochemistry, cell biology, and clinical biochemistry. Published by Wiley, this journal has maintained an esteemed reputation since its inception in 1983, bridging decades of scientific advancements and contributions until 2024. With ISSN 0263-6484 and E-ISSN 1099-0844, it serves as a vital resource for researchers, professionals, and students. The journal is classified in quartiles Q2 and Q3 across various categories in the 2023 rankings, showcasing its impact and significance within the academic community. Highlighting essential studies in medicinal biochemistry and cellular functionalities, CELL BIOCHEMISTRY AND FUNCTION not only presents cutting-edge research but also encourages interdisciplinary collaboration, thereby advancing the understanding of biochemical processes that underlie living systems. With no open access currently available, readers are encouraged to access articles through institutional subscriptions or individual purchases, ensuring exclusive engagement with the latest scientific findings in this dynamic field.

Reports of Biochemistry and Molecular Biology, published by VARASTEGAN INST MEDICAL SCIENCES, is a distinguished open access journal dedicated to advancing the fields of biochemistry and molecular biology. Since its inception in 2012, the journal has fostered a platform for researchers and professionals to disseminate their findings, contributing to a richer understanding of biochemical processes and molecular mechanisms. With a focus on innovative research and technology, the journal has established itself as a significant resource within its field, being classified in the Q3 category for Biochemistry and Molecular Biology by 2023. Notably, it has achieved respectable Scopus rankings, including a rank of #40/72 in Biochemistry (medical) as well as a common ground across multiple related categories. The journal’s commitment to open access ensures that its valuable content is freely available to the global scientific community, facilitating knowledge sharing among students, researchers, and professionals alike. Located in Mashhad, Iran, Reports of Biochemistry and Molecular Biology serves as a bridge between cutting-edge research and practical applications in the biochemistry and molecular biology domains.

IUBMB LIFE is a prestigious, peer-reviewed journal published by WILEY, dedicated to advancing the fields of biochemistry, molecular biology, and cell biology. With an impressive impact factor and consistently ranked in the Q1 and Q2 categories across multiple relevant disciplines—including Biochemistry, Genetics, and Clinical Biochemistry—this journal has established itself as a leading platform for disseminating innovative research and critical reviews that propel scientific discovery. The journal spans a converged publication period from 1999 to 2024, providing comprehensive insights into the dynamic landscape of biochemical research. Researchers, professionals, and students alike are invited to explore its Open Access options, ensuring that groundbreaking studies are accessible to a global audience. As it continues to shape the future of life sciences, IUBMB LIFE remains a vital resource for those seeking to enrich their understanding and contribute to these rapidly evolving fields.

ANTIOXIDANTS & REDOX SIGNALING, published by MARY ANN LIEBERT, INC, is a premier journal dedicated to advancing the understanding of oxidative stress, antioxidants, and redox biology in various health contexts. With an impressive track record since its inception in 1999, this journal has continually evolved, currently converging towards 2024 as a core resource for researchers in biochemistry, cell biology, and molecular medicine. It holds a distinguished position in Q1 across several categories, including Biochemistry, Cell Biology, and Clinical Biochemistry, reflecting its critical role in disseminating high-quality research that impacts the fields of physiology and medicine. Despite not being an open-access journal, ANTIOXIDANTS & REDOX SIGNALING is renowned for its rigorous peer-review process and wide reach, ensuring that published articles are both influential and accessible to professionals, academia, and students alike. Researchers can benefit from its comprehensive articles that delve into cutting-edge discoveries and emerging therapies related to oxidative stress and its biological implications.

Molecular Metabolism is a premier, open-access journal published by Elsevier, dedicated to advancing the understanding of metabolic processes at the molecular level. With an ISSN of 2212-8778 and a proud presence in Germany, the journal has made significant contributions to the fields of Cell Biology and Molecular Biology, consistently achieving a Q1 ranking in both categories as of 2023. The journal’s scope encompasses cutting-edge research that explores metabolic pathways, their regulation, and implications for human health, underscoring the interplay between metabolism and various biological functions. Researchers and professionals benefit from the journal’s robust visibility, as it ranks #40 among 410 journals in Molecular Biology and #35 among 285 in Cell Biology according to Scopus metrics, placing it in the top 10 percentile in its field. With open access since 2012, Molecular Metabolism ensures that groundbreaking research is available to all, fostering a collaborative and inclusive academic environment. Its commitment to excellence and accessibility makes it an invaluable resource for those invested in metabolic research.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

BIOFACTORS, an esteemed journal published by Wiley, serves as a pivotal resource in the fields of Biochemistry, Clinical Biochemistry, and Molecular Medicine. With ISSN 0951-6433 and E-ISSN 1872-8081, the journal has established its reputation since its inception in 1988, showcasing a rich history of scientific inquiry and innovation. Recognized for its high academic standards, it currently holds a Q1 ranking in key categories, including Biochemistry and Medicine (miscellaneous), and ranks in the top 10% for Clinical Biochemistry according to Scopus metrics, reflecting its impact and influence in the scientific community. Although it does not offer Open Access, BIOFACTORS provides researchers the opportunity to publish and disseminate high-quality studies that advance our understanding of biological factors and their clinical implications. The journal actively encourages contributions that bridge the gap between laboratory findings and clinical applications, making it a vital platform for both seasoned researchers and emerging scholars in the life sciences.